Medical Educational Resource
We're accelerating the delivery of treatments and cures.
Leveraging Genetic Testing to Optimize Early Intervention in SMA & DMD
Activity Snapshot
This program is supported in part by independent medical education grants from Catalyst Pharmaceuticals, Novartis and Scholar Rock.
Faculty
Boston Children's Hospital
University of Rochester Medical Center
Nationwide Children’s Hospital
This webinar will examine how pre-natal testing and newborn screening can inform early intervention opportunities in spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).
Recognize opportunities for early diagnosis through prenatal testing, newborn screening, and genetic testing.
Apply current evidence to support timely treatment initiation.
Identify practical considerations for use of current and emerging therapies.
To earn your continuing education (CE) credits, verify your attendance, then submit the evaluation using the link below.
Your certificate will be issued upon completing this evaluation: https://akhcme.com/content/leveraging-genetic-testing-optimize-early-int...
Login or Create an account in the system. (All first time users are required to create an account).
Proceed to “Register/Take Course” Tab to complete the Course Evaluation & Certificate steps for the activity.
If you have questions about this CE activity, please contact AKH Inc at bethany@akhcme.com.
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
